

# EMEA (Europe, Middle East and Africa) Multiple Myeloma Drugs Market Report 2017

https://marketpublishers.com/r/EDEE4F476F6EN.html

Date: January 2018 Pages: 106 Price: US\$ 4,000.00 (Single User License) ID: EDEE4F476F6EN

# Abstracts

In this report, the EMEA Multiple Myeloma Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Multiple Myeloma Drugs for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Multiple Myeloma Drugs market competition by top manufacturers/players, with Multiple Myeloma Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

Novartis

Bristol-Myers Squibb Company

Takeda Oncology

Johnson & Johnson



#### **Celgene Corporation**

Apotex

**Emcure Pharmaceuticals** 

Amgen

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Melphalan
Carmustine
Cyclophosphamide
Daratumumab
Doxorubicin Hydrochloride Liposome
Elotuzumab
Panobinostat
Other medication

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

applicaton 1

applicaton 2



If you have any special requirements, please let us know and we will offer you the report as you want.



# Contents

EMEA (Europe, Middle East and Africa) Multiple Myeloma Drugs Market Report 2017

#### 1 MULTIPLE MYELOMA DRUGS OVERVIEW

- 1.1 Product Overview and Scope of Multiple Myeloma Drugs
- 1.2 Classification of Multiple Myeloma Drugs

1.2.1 EMEA Multiple Myeloma Drugs Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 EMEA Multiple Myeloma Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016

- 1.2.3 Melphalan
- 1.2.4 Carmustine
- 1.2.5 Cyclophosphamide
- 1.2.6 Daratumumab
- 1.2.7 Doxorubicin Hydrochloride Liposome
- 1.2.8 Elotuzumab
- 1.2.9 Panobinostat
- 1.2.10 Other medication
- 1.3 EMEA Multiple Myeloma Drugs Market by Application/End Users
- 1.3.1 EMEA Multiple Myeloma Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  - 1.3.2 applicaton
  - 1.3.3 applicaton
- 1.4 EMEA Multiple Myeloma Drugs Market by Region

1.4.1 EMEA Multiple Myeloma Drugs Market Size (Value) Comparison by Region (2012-2022)

- 1.4.2 Europe Status and Prospect (2012-2022)
- 1.4.3 Middle East Status and Prospect (2012-2022)
- 1.4.4 Africa Status and Prospect (2012-2022)
- 1.5 EMEA Market Size (Value and Volume) of Multiple Myeloma Drugs (2012-2022)
- 1.5.1 EMEA Multiple Myeloma Drugs Sales and Growth Rate (2012-2022)
- 1.5.2 EMEA Multiple Myeloma Drugs Revenue and Growth Rate (2012-2022)

#### 2 EMEA MULTIPLE MYELOMA DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Multiple Myeloma Drugs Market Competition by Players/Manufacturers



2.1.1 EMEA Multiple Myeloma Drugs Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Multiple Myeloma Drugs Revenue and Share by Players (2012-2017)

2.1.3 EMEA Multiple Myeloma Drugs Sale Price by Players (2012-2017)

2.2 EMEA Multiple Myeloma Drugs (Volume and Value) by Type/Product Category

2.2.1 EMEA Multiple Myeloma Drugs Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Multiple Myeloma Drugs Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Multiple Myeloma Drugs Sale Price by Type (2012-2017)

2.3 EMEA Multiple Myeloma Drugs (Volume) by Application

- 2.4 EMEA Multiple Myeloma Drugs (Volume and Value) by Region
- 2.4.1 EMEA Multiple Myeloma Drugs Sales and Market Share by Region (2012-2017)

2.4.3 EMEA Multiple Myeloma Drugs Sales Price by Region (2012-2017)

### 3 EUROPE MULTIPLE MYELOMA DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Multiple Myeloma Drugs Sales and Value (2012-2017)

3.1.1 Europe Multiple Myeloma Drugs Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Multiple Myeloma Drugs Revenue and Growth Rate (2012-2017)

3.2 Europe Multiple Myeloma Drugs Sales and Market Share by Type

3.3 Europe Multiple Myeloma Drugs Sales and Market Share by Application

3.4 Europe Multiple Myeloma Drugs Sales Volume and Value (Revenue) by Countries

- 3.4.1 Europe Multiple Myeloma Drugs Sales Volume by Countries (2012-2017)
- 3.4.2 Europe Multiple Myeloma Drugs Revenue by Countries (2012-2017)
- 3.4.3 Germany Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 3.4.4 France Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

3.4.5 UK Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

3.4.6 Russia Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

3.4.7 Italy Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

3.4.8 Benelux Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

### 4 MIDDLE EAST MULTIPLE MYELOMA DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Multiple Myeloma Drugs Sales and Value (2012-2017)

4.1.1 Middle East Multiple Myeloma Drugs Sales Volume and Growth Rate (2012-2017)

<sup>2.4.2</sup> EMEA Multiple Myeloma Drugs Revenue and Market Share by Region (2012-2017)



4.1.2 Middle East Multiple Myeloma Drugs Revenue and Growth Rate (2012-2017)

4.2 Middle East Multiple Myeloma Drugs Sales and Market Share by Type

4.3 Middle East Multiple Myeloma Drugs Sales and Market Share by Application

4.4 Middle East Multiple Myeloma Drugs Sales Volume and Value (Revenue) by Countries

4.4.1 Middle East Multiple Myeloma Drugs Sales Volume by Countries (2012-2017)

- 4.4.2 Middle East Multiple Myeloma Drugs Revenue by Countries (2012-2017)
- 4.4.3 Saudi Arabia Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 4.4.4 Israel Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 4.4.5 UAE Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 4.4.6 Iran Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

## 5 AFRICA MULTIPLE MYELOMA DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Multiple Myeloma Drugs Sales and Value (2012-2017)

- 5.1.1 Africa Multiple Myeloma Drugs Sales Volume and Growth Rate (2012-2017)
- 5.1.2 Africa Multiple Myeloma Drugs Revenue and Growth Rate (2012-2017)
- 5.2 Africa Multiple Myeloma Drugs Sales and Market Share by Type
- 5.3 Africa Multiple Myeloma Drugs Sales and Market Share by Application
- 5.4 Africa Multiple Myeloma Drugs Sales Volume and Value (Revenue) by Countries
- 5.4.1 Africa Multiple Myeloma Drugs Sales Volume by Countries (2012-2017)
- 5.4.2 Africa Multiple Myeloma Drugs Revenue by Countries (2012-2017)
- 5.4.3 South Africa Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 5.4.4 Nigeria Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 5.4.5 Egypt Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)
- 5.4.6 Algeria Multiple Myeloma Drugs Sales and Growth Rate (2012-2017)

## 6 EMEA MULTIPLE MYELOMA DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

- 6.1 Novartis
  - 6.1.1 Company Basic Information, Manufacturing Base and Competitors
  - 6.1.2 Multiple Myeloma Drugs Product Type, Application and Specification
    - 6.1.2.1 Product A
    - 6.1.2.2 Product B
- 6.1.3 Novartis Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  - 6.1.4 Main Business/Business Overview



- 6.2 Bristol-Myers Squibb Company
- 6.2.1 Company Basic Information, Manufacturing Base and Competitors
- 6.2.2 Multiple Myeloma Drugs Product Type, Application and Specification
- 6.2.2.1 Product A
- 6.2.2.2 Product B

6.2.3 Bristol-Myers Squibb Company Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

- 6.2.4 Main Business/Business Overview
- 6.3 Takeda Oncology
  - 6.3.1 Company Basic Information, Manufacturing Base and Competitors
  - 6.3.2 Multiple Myeloma Drugs Product Type, Application and Specification
  - 6.3.2.1 Product A
  - 6.3.2.2 Product B

6.3.3 Takeda Oncology Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

- 6.3.4 Main Business/Business Overview
- 6.4 Johnson & Johnson
  - 6.4.1 Company Basic Information, Manufacturing Base and Competitors
  - 6.4.2 Multiple Myeloma Drugs Product Type, Application and Specification
  - 6.4.2.1 Product A
  - 6.4.2.2 Product B

6.4.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

- 6.4.4 Main Business/Business Overview
- 6.5 Celgene Corporation
  - 6.5.1 Company Basic Information, Manufacturing Base and Competitors
  - 6.5.2 Multiple Myeloma Drugs Product Type, Application and Specification
  - 6.5.2.1 Product A
  - 6.5.2.2 Product B

6.5.3 Celgene Corporation Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

- 6.5.4 Main Business/Business Overview
- 6.6 Apotex
  - 6.6.1 Company Basic Information, Manufacturing Base and Competitors
  - 6.6.2 Multiple Myeloma Drugs Product Type, Application and Specification
  - 6.6.2.1 Product A
  - 6.6.2.2 Product B

6.6.3 Apotex Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)



- 6.6.4 Main Business/Business Overview
- 6.7 Emcure Pharmaceuticals
- 6.7.1 Company Basic Information, Manufacturing Base and Competitors
- 6.7.2 Multiple Myeloma Drugs Product Type, Application and Specification
- 6.7.2.1 Product A
- 6.7.2.2 Product B

6.7.3 Emcure Pharmaceuticals Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Amgen

- 6.8.1 Company Basic Information, Manufacturing Base and Competitors
- 6.8.2 Multiple Myeloma Drugs Product Type, Application and Specification
- 6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Amgen Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

#### 7 MULTIPLE MYELOMA DRUGS MANUFACTURING COST ANALYSIS

- 7.1 Multiple Myeloma Drugs Key Raw Materials Analysis
  - 7.1.1 Key Raw Materials
  - 7.1.2 Price Trend of Key Raw Materials
  - 7.1.3 Key Suppliers of Raw Materials
- 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
  - 7.2.1 Raw Materials
  - 7.2.2 Labor Cost
- 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Multiple Myeloma Drugs

#### **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

- 8.1 Multiple Myeloma Drugs Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Multiple Myeloma Drugs Major Manufacturers in 2016
- 8.4 Downstream Buyers

#### 9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS



- 9.1 Marketing Channel
  - 9.1.1 Direct Marketing
  - 9.1.2 Indirect Marketing
  - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
  - 9.2.1 Pricing Strategy
  - 9.2.2 Brand Strategy
- 9.2.3 Target Client
- 9.3 Distributors/Traders List

#### 10 MARKET EFFECT FACTORS ANALYSIS

- 10.1 Technology Progress/Risk
- 10.1.1 Substitutes Threat
- 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

#### 11 EMEA MULTIPLE MYELOMA DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Multiple Myeloma Drugs Sales, Revenue and Price Forecast (2017-2022)

11.1.1 EMEA Multiple Myeloma Drugs Sales and Growth Rate Forecast (2017-2022)

11.1.2 EMEA Multiple Myeloma Drugs Revenue and Growth Rate Forecast (2017-2022)

11.1.3 EMEA Multiple Myeloma Drugs Price and Trend Forecast (2017-2022)

11.2 EMEA Multiple Myeloma Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.3 Europe Multiple Myeloma Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.4 Middle Eastt Multiple Myeloma Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.5 Africa Multiple Myeloma Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.6 EMEA Multiple Myeloma Drugs Sales Forecast by Type (2017-2022)

11.7 EMEA Multiple Myeloma Drugs Sales Forecast by Application (2017-2022)

#### 12 RESEARCH FINDINGS AND CONCLUSION



#### **13 APPENDIX**

- 13.1 Methodology/Research Approach
  - 13.1.1 Research Programs/Design
  - 13.1.2 Market Size Estimation
  - 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
  - 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.



# List Of Tables

#### LIST OF TABLES AND FIGURES

Figure Product Picture of Multiple Myeloma Drugs Figure EMEA Multiple Myeloma Drugs Sales Volume (K Units) by Type (2012-2022) Figure EMEA Multiple Myeloma Drugs Sales Volume Market Share by Type (Product Category) in 2016 **Figure Melphalan Product Picture Figure Carmustine Product Picture** Figure Cyclophosphamide Product Picture Figure Daratumumab Product Picture Figure Doxorubicin Hydrochloride Liposome Product Picture Figure Elotuzumab Product Picture **Figure Panobinostat Product Picture** Figure Other medication Product Picture Figure EMEA Multiple Myeloma Drugs Sales Volume (K Units) by Application (2012 - 2022)Figure EMEA Sales Market Share of Multiple Myeloma Drugs by Application in 2016 Figure application 1 Examples Table Key Downstream Customer in application Figure application 2 Examples Table Key Downstream Customer in applicaton Figure EMEA Multiple Myeloma Drugs Market Size (Million USD) by Region (2012 - 2022)Figure Europe Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012 - 2022)Figure Europe Multiple Myeloma Drugs Revenue (Million USD) Status and Forecast by Countries Figure Middle East Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012 - 2022)Figure Middle East Multiple Myeloma Drugs Revenue (Million USD) Status and Forecast by Countries Figure Africa Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012 - 2022)Figure Africa Multiple Myeloma Drugs Revenue (Million USD) Status and Forecast by Countries Figure EMEA Multiple Myeloma Drugs Sales Volume and Growth Rate (2012-2022) Figure EMEA Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate



(2012-2022)

Figure EMEA Multiple Myeloma Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)

Table EMEA Multiple Myeloma Drugs Sales Volume (K Units) of Major Players (2012-2017)

Table EMEA Multiple Myeloma Drugs Sales Share by Players (2012-2017)

Figure 2016 Multiple Myeloma Drugs Sales Share by Players

Figure 2017 Multiple Myeloma Drugs Sales Share by Players

Figure EMEA Multiple Myeloma Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table EMEA Multiple Myeloma Drugs Revenue (Million USD) by Players (2012-2017) Table EMEA Multiple Myeloma Drugs Revenue Share by Players (2012-2017)

Table 2016 EMEA Multiple Myeloma Drugs Revenue Share by Players

Table 2017 EMEA Multiple Myeloma Drugs Revenue Share by Players

Table EMEA Multiple Myeloma Drugs Sale Price (USD/Unit) by Players (2012-2017)

Table EMEA Multiple Myeloma Drugs Sales (K Units) and Market Share by Type (2012-2017)

 Table EMEA Multiple Myeloma Drugs Sales Share by Type (2012-2017)

Figure Sales Market Share of Multiple Myeloma Drugs by Type (2012-2017)

Figure EMEA Multiple Myeloma Drugs Sales Market Share by Type (2012-2017) Table EMEA Multiple Myeloma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Multiple Myeloma Drugs Revenue Share by Type (2012-2017) Figure Revenue Market Share of Multiple Myeloma Drugs by Type in 2016 Table EMEA Multiple Myeloma Drugs Sale Price (USD/Unit) by Type (2012-2017) Table EMEA Multiple Myeloma Drugs Sales (K Units) and Market Share by Application (2012-2017)

Table EMEA Multiple Myeloma Drugs Sales Share by Application (2012-2017) Figure Sales Market Share of Multiple Myeloma Drugs by Application (2012-2017) Figure EMEA Multiple Myeloma Drugs Sales Market Share by Application in 2016 Table EMEA Multiple Myeloma Drugs Sales (K Units) and Market Share by Region (2012-2017)

Table EMEA Multiple Myeloma Drugs Sales Share by Region (2012-2017) Figure Sales Market Share of Multiple Myeloma Drugs by Region (2012-2017)

Figure EMEA Multiple Myeloma Drugs Sales Market Share in 2016

Table EMEA Multiple Myeloma Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Multiple Myeloma Drugs Revenue Share by Region (2012-2017) Figure Revenue Market Share of Multiple Myeloma Drugs by Region (2012-2017)



Figure EMEA Multiple Myeloma Drugs Revenue Market Share Regions in 2016 Table EMEA Multiple Myeloma Drugs Sales Price (USD/Unit) by Region (2012-2017) Figure Europe Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Europe Multiple Myeloma Drugs Revenue and Growth Rate (2012-2017) Table Europe Multiple Myeloma Drugs Sales (K Units) by Type (2012-2017) Table Europe Multiple Myeloma Drugs Market Share by Type (2012-2017) Figure Europe Multiple Myeloma Drugs Market Share by Type in 2016 Table Europe Multiple Myeloma Drugs Sales (K Units) by Application (2012-2017) Table Europe Multiple Myeloma Drugs Market Share by Application (2012-2017) Figure Europe Multiple Myeloma Drugs Market Share by Application in 2016 Table Europe Multiple Myeloma Drugs Sales (K Units) by Countries (2012-2017) Table Europe Multiple Myeloma Drugs Sales Market Share by Countries (2012-2017) Figure Europe Multiple Myeloma Drugs Sales Market Share by Countries (2012-2017) Figure Europe Multiple Myeloma Drugs Sales Market Share by Countries in 2016 Table Europe Multiple Myeloma Drugs Revenue (Million USD) by Countries (2012 - 2017)

Table Europe Multiple Myeloma Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Multiple Myeloma Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Multiple Myeloma Drugs Revenue Market Share by Countries in 2016 Figure Germany Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure France Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure UK Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Russia Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Italy Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Benelux Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Benelux Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Middle East Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Middle East Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Middle East Multiple Myeloma Drugs Sales (K Units) by Type (2012-2017) Table Middle East Multiple Myeloma Drugs Market Share by Type (2012-2017) Figure Middle East Multiple Myeloma Drugs Market Share by Type (2012-2017) Table Middle East Multiple Myeloma Drugs Sales (K Units) by Applications (2012-2017) Table Middle East Multiple Myeloma Drugs Market Share by Applications (2012-2017) Figure Middle East Multiple Myeloma Drugs Sales Market Share by Application in 2016 Table Middle East Multiple Myeloma Drugs Sales Volume (K Units) by Countries (2012-2017)



Table Middle East Multiple Myeloma Drugs Sales Volume Market Share by Countries (2012-2017)

Figure Middle East Multiple Myeloma Drugs Sales Volume Market Share by Countries in 2016

Table Middle East Multiple Myeloma Drugs Revenue (Million USD) by Countries (2012-2017)

Table Middle East Multiple Myeloma Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Multiple Myeloma Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Multiple Myeloma Drugs Revenue Market Share by Countries in 2016

Figure Saudi Arabia Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Israel Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure UAE Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Iran Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Africa Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Africa Multiple Myeloma Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Africa Multiple Myeloma Drugs Sales (K Units) by Type (2012-2017) Table Africa Multiple Myeloma Drugs Sales Market Share by Type (2012-2017) Figure Africa Multiple Myeloma Drugs Sales Market Share by Type (2012-2017) Figure Africa Multiple Myeloma Drugs Sales Market Share by Type in 2016 Table Africa Multiple Myeloma Drugs Sales (K Units) by Application (2012-2017) Table Africa Multiple Myeloma Drugs Sales Market Share by Application (2012-2017) Figure Africa Multiple Myeloma Drugs Sales Market Share by Application (2012-2017) Table Africa Multiple Myeloma Drugs Sales Volume (K Units) by Countries (2012-2017) Table Africa Multiple Myeloma Drugs Sales Market Share by Countries (2012-2017) Figure Africa Multiple Myeloma Drugs Sales Market Share by Countries (2012-2017) Figure Africa Multiple Myeloma Drugs Sales Market Share by Countries in 2016 Table Africa Multiple Myeloma Drugs Revenue (Million USD) by Countries (2012-2017) Table Africa Multiple Myeloma Drugs Revenue Market Share by Countries (2012-2017) Figure Africa Multiple Myeloma Drugs Revenue Market Share by Countries (2012-2017) Figure Africa Multiple Myeloma Drugs Revenue Market Share by Countries in 2016 Figure South Africa Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012 - 2017)

Figure Nigeria Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Egypt Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)



Figure Algeria Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Table Novartis Multiple Myeloma Drugs Basic Information List

Table Novartis Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Novartis Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Novartis Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Novartis Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

Table Bristol-Myers Squibb Company Multiple Myeloma Drugs Basic Information List

Table Bristol-Myers Squibb Company Multiple Myeloma Drugs Sales (K Units),

Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb Company Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Bristol-Myers Squibb Company Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Bristol-Myers Squibb Company Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

Table Takeda Oncology Multiple Myeloma Drugs Basic Information List

Table Takeda Oncology Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Takeda Oncology Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Takeda Oncology Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Takeda Oncology Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

Table Johnson & Johnson Multiple Myeloma Drugs Basic Information List

Table Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Johnson & Johnson Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Johnson & Johnson Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Johnson & Johnson Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

 Table Celgene Corporation Multiple Myeloma Drugs Basic Information List

Table Celgene Corporation Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Celgene Corporation Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)



Figure Celgene Corporation Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Celgene Corporation Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

Table Apotex Multiple Myeloma Drugs Basic Information List

Table Apotex Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Apotex Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Apotex Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Apotex Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

Table Emcure Pharmaceuticals Multiple Myeloma Drugs Basic Information List

Table Emcure Pharmaceuticals Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Emcure Pharmaceuticals Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Emcure Pharmaceuticals Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Emcure Pharmaceuticals Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

Table Amgen Multiple Myeloma Drugs Basic Information List

Table Amgen Multiple Myeloma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Amgen Multiple Myeloma Drugs Sales (K Units) and Growth Rate (2012-2017) Figure Amgen Multiple Myeloma Drugs Sales Market Share in EMEA (2012-2017)

Figure Amgen Multiple Myeloma Drugs Revenue Market Share in EMEA (2012-2017)

 Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Multiple Myeloma Drugs

Figure Manufacturing Process Analysis of Multiple Myeloma Drugs

Figure Multiple Myeloma Drugs Industrial Chain Analysis

Table Raw Materials Sources of Multiple Myeloma Drugs Major Manufacturers in 2016

Table Major Buyers of Multiple Myeloma Drugs

Table Distributors/Traders List

Figure EMEA Multiple Myeloma Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)

Figure EMEA Multiple Myeloma Drugs Revenue and Growth Rate Forecast (2017-2022) Figure EMEA Multiple Myeloma Drugs Price (USD/Unit) and Trend Forecast (2017-2022)



Table EMEA Multiple Myeloma Drugs Sales (K Units) Forecast by Region (2017-2022) Figure EMEA Multiple Myeloma Drugs Sales Market Share Forecast by Region (2017-2022)

Table EMEA Multiple Myeloma Drugs Revenue (Million USD) Forecast by Region (2017-2022)

Figure EMEA Multiple Myeloma Drugs Revenue Market Share Forecast by Region (2017-2022)

Table Europe Multiple Myeloma Drugs Sales (K Units) Forecast by Countries (2017-2022)

Figure Europe Multiple Myeloma Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Europe Multiple Myeloma Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Europe Multiple Myeloma Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Middle East Multiple Myeloma Drugs Sales (K Units) Forecast by Countries (2017-2022)

Figure Middle East Multiple Myeloma Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Middle East Multiple Myeloma Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Middle East Multiple Myeloma Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Africa Multiple Myeloma Drugs Sales (K Units) Forecast by Countries (2017-2022)

Figure Africa Multiple Myeloma Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Africa Multiple Myeloma Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Africa Multiple Myeloma Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table EMEA Multiple Myeloma Drugs Sales (K Units) Forecast by Type (2017-2022) Figure EMEA Multiple Myeloma Drugs Sales Market Share Forecast by Type (2017-2022)

Table EMEA Multiple Myeloma Drugs Sales (K Units) Forecast by Application (2017-2022)

Figure EMEA Multiple Myeloma Drugs Sales Market Share Forecast by Application (2017-2022)

Table Research Programs/Design for This Report



Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Sources



#### I would like to order

Product name: EMEA (Europe, Middle East and Africa) Multiple Myeloma Drugs Market Report 2017 Product link: <u>https://marketpublishers.com/r/EDEE4F476F6EN.html</u>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

#### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/EDEE4F476F6EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970